

The actions of phloridzin on sodium ion transporters and potential difference in nasal airway epithelium.

Submission date 30/09/2005	Recruitment status Stopped	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/09/2005	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 05/04/2011	Condition category Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Emma Baker

Contact details

St George's Hospital
University of London
Cranmer Terrace
Tooting
London
United Kingdom
SW17 0RE
+44 (0)20 8725 5383
ebaker@sgul.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0236143719

Study information

Scientific Title

Study objectives

To determine whether nasal application of phloridzin, a sodium-glucose co-transporter (SGLT-1) inhibitor, alters nasal potential difference demonstrating SGLT-1 function.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Wandsworth REC (UK)

Study design

In vivo pharmacological study

Primary study design

Interventional

Secondary study design

Other

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Respiratory: Chronic obstructive pulmonary disease (COPD)

Interventions

Nasal potential difference: between the 'sensing' electrode in contact with the nasal epithelium, and the 'reference' electrode, a butterfly needle inserted under the skin of the forearm, is measured. Phloridzin in Ringer's solution will then be additionally perfused onto the nasal epithelium and any further change in nasal PD recorded. On a second visit a repeat of the above protocol will be carried out with phloridzin followed by amiloride.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

phloridzin

Primary outcome measure

Changes in the measured nasal potential difference with phloridzin

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/10/2002

Completion date

01/12/2007

Reason abandoned (if study stopped)

Not a clinical trial

Eligibility

Key inclusion criteria

Healthy, non-smoking volunteers with normal nasal mucosa and random plasma glucose <7mmol /l.

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

10

Key exclusion criteria

1. Nasal disease
2. Diabetes mellitus
3. Pregnancy

Date of first enrolment

01/10/2002

Date of final enrolment

01/12/2007

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

St George's Hospital

London

United Kingdom

SW17 0RE

Sponsor information

Organisation

Department of Health

Sponsor details

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

+44 (0)20 7307 2622

dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

<http://www.dh.gov.uk/Home/fs/en>

Funder(s)

Funder type

Government

Funder Name

St George's Healthcare NHS Trust (UK)

Funder Name

No External Funding

Funder Name

NHS R&D Support Funding

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration